Gerald Cochran

Gerald Cochran, MSW, PhD

Languages spoken: Spanish, English

Academic Information

Departments Primary - Internal Medicine , Adjunct - Population Health Sciences , Adjunct - Psychiatry

Divisions: Adult Psychiatry , Epidemiology

Gerald (Jerry) Cochran is a Professor in the Department of Internal Medicine, Division of Epidemiology at the University of Utah and serves as the Director of Research for the Program on Addiction Research, Clinical Care, Knowledge, and Advocacy within the Division of Epidemiology. He also has an adjunct appointment with the University of Utah Department of Psychiatry and is core faculty with the Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center of Innovation within the VA Salt Lake City Health Care System.

Dr. Cochran’s area of expertise involves identifying and studying appropriate care for underserved populations in health care settings, with particular emphasis on individuals who use drugs and alcohol. He has extensive expertise in clinical- and system-level behavioral health services research. Dr. Cochran’s work has focused on development and testing of evidence-based practices for addressing opioid and other substance use in health care settings. Dr. Cochran’s work aims to improve substance use prevention and treatment services.

Research Statement

Dr. Cochran earned his Ph.D. from The University of Texas at Austin School of Social Work and completed postdoctoral training with the Johns Hopkins School of Medicine, Department of Psychiatry and Behavioral Sciences. Dr. Cochran’s research interests are centered on behavioral health services research. His area of expertise involves identifying and studying appropriate care for underserved populations in healthcare settings, with particular emphasis on individuals who misuse drugs and alcohol. Dr. Cochran’s work aims to improve substance abuse prevention and treatment services provided in health care settings.

Education History

Undergraduate Brigham Young University
 BS
Graduate Training University of Utah
 MSW
Doctoral Training The University of Texas at Austin
 PhD
Research Fellow Johns Hopkins University School of Medicine
 Postdoctoral Research Fellow

Selected Publications

Journal Article

  1. Cochran G, Stitzer M, Campbell AN, Hu MC, Vandrey R, Nunes EV (2015). Web-based treatment for substance use disorders: differential effects by primary substance. Addict Behav, 45, 191-4. (Read full article)
  2. Field CA, Cochran G, Caetano (2013). Treatment utilization and unmet treatment need among Hispanics following brief intervention. Alcoholism, clinical and experimental research, 37(2), 300-7. (Read full article)
  3. Kirisci L, Tarter R, Reynolds M, Hayes K, Cochran G, Vanyukov (2020). Derivation and Assessment of the Opioid Use Disorder Severity Scale: Prediction of Health, Psychological and Social Adjustment Problems. The American journal of drug and alcohol abuse, 46(6), 699-707.
  4. Webb K, Cernasev A, Li M, Gatwood J, Cochran G, Hohmeier K (2020). An exploratory study of pharmacist perceptions of opioid interventions for acute pain. The Journal of pharmacy technology, 37(1), 36-44.
  5. Moyo P, Gellad W, Sabik L, Cochran G, Cole E, Kelley D, Donohue J (2019). Opioid Prescribing Safety Measures in Medicaid Enrollees with and without Cancer. American journal of preventive medicine, 57(4), 540-544.
  6. Cochran G, Field C, DiClemente C, Caetano (2016). Latent Classes Among Recipients of a Brief Alcohol Intervention: A Replication Analysis. Behavioral medicine (Washington, D.C.), 42(1), 29-38. (Read full article)
  7. Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, Donohue J (2016). Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction (Abingdon, England), 111(5), 892-902. (Read full article)
  8. Krans EE, Cochran G, Bogen D (2015). Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. Clinical obstetrics and gynecology, 58(2), 370-9. (Read full article)
  9. Field CA, Cochran G, Caetano (2012). Ethnic differences in the effect of drug use and drug dependence on brief motivational interventions targeting alcohol use. Drug and alcohol dependence, 126(1-2), 21-6. (Read full article)
  10. Cochran G, McCarthy R, Gordon AJ, Tarter R (2017). Opioid medication misuse among unhealthy drinkers. Drug and alcohol dependence, 179, 13-17. (Read full article)
  11. Cochran G, Chen Q, Field C, Seybert A, Hruschak V, Jaber A, Gordon AJ, Tarter (2019). A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial. Drug and alcohol dependence, 205, 107570.
  12. Cole E, Drake C, DiDomenico E, Sharbaugh M, Kim JY, Nagy D, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CC-H, Kmiec J, Kelley D, Donohue JM (2021). Patterns of Clinic Switching and Continuity of Medication for Opioid Use Disorder in a Medicaid-Enrolled Population. Drug and alcohol dependence, 221, 108633.
  13. Cochran G, Brown J, Yu Z, Frede S, Bryan A, Ferguson A, Bayyari N, Snyder M, Charron E, Ghitza U, Olatunde L, Winhusen (2021). Validation and Threshold Identification of a Prescription Drug Monitoring Program Clinical Opioid Risk Metric with the WHO Alcohol, Smoking, and Substance Involvement Screening Test Drug and Alcohol Dependence. Drug and alcohol dependence, 228, 1-8.
  14. Cole ES, DiDomenico E, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CH, Kim JY, Kmiec J, Kelley D, Donohue J (2019). The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder. Journal of general internal medicine, 34(6), 936-943. (Read full article)
  15. Guo J, Lo-Ciganic W-H, Yang Q, Huang J, Weiss J, Cochran G, Malone D, Kuza CC, Gordon AJ, Donohue J, Gellad (2020). Predicting Mortality Risk after a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. Journal of general internal medicine, 36(4), 908-915.
  16. Tarter R, Kirisci L, Cochran G, Seybert A, Reynolds M, Vanyukov (2020). Forecasting Opioid Use Disorder at 25 Years of Age in 16-Year Old Adolescents. The Journal of pediatrics, 225, 207-213.el.
  17. Field CA, Cochran G, Foulkrod K, Brown (2011). Trauma healthcare providers' knowledge of alcohol abuse. The Journal of trauma, 70(6), 1437-43. (Read full article)
  18. Frazier W, Cochran G, Lo-Ciganic WH, Gellad WF, Gordon AJ, Chang CH, Donohue J (2017). Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid. JAMA, 318(8), 750-752. (Read full article)
  19. Cochran G, Gordon AJ, Lo-Ciganic WH, Gellad WF, Frazier W, Lobo C, Chang CH, Zheng P, Donohue J (2017). An Examination of Claims-based Predictors of Overdose from a Large Medicaid Program. Medical care, 55(3), 291-298. (Read full article)
  20. Sharareh N, Hess R, White S, Dunn A, Singer P, Cochran G (2020). A Vulnerability Assessment for the HCV Infections Associated with Injection Drug Use. Preventive medicine, 134, 106040.
  21. Bahorik AL, Greeno CG, Cochran G, Cornelius JR, Eack S (2017). Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia. Psychiatry research, 253, 391-397. (Read full article)
  22. Cochran (2010). Analysis of the Uniform Accident And Sickness Policy Provision Law: lessons for social work practice, policy, and research. Social work in health care, 49(7), 647-68. (Read full article)
  23. Cochran G, Montgomery KL, Bell (2012). Translating evidence-based practices into policy: a case study in Texas. Social work in health care, 51(5), 383-401. (Read full article)
  24. Hruschak V Msw Rsw, Cochran (2017). Psychosocial and environmental factors in the prognosis of individuals with chronic pain and comorbid mental health. Social work in health care, 56(7), 573-587. (Read full article)
  25. Cochran G, Davis (2012). Social work and the Uniform Accident and Sickness Policy Provision Law: a pilot project. Social work, 57(1), 39-48. (Read full article)
  26. Gadd S, Cox N, Samuelson J, Kenney A, Turner K, Cochran G (2021). Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective. Therapeutic drug monitoring, 43, 35-41.
  27. Theisen KM, Myrga JM, Hale N, Cochran G, Sewall C, Macleod LC, Jacobs BL, Davies B (2019). Excessive Opioid Prescribing After Major Urologic Procedures. Urology, 123, 101-107. (Read full article)
  28. Kenney A, Cox N, Bryan M, Cochran G (2021). Brief intervention medication therapy management: The establishment of an opioid misuse intervention model delivered in community pharmacy. American journal of health-system pharmacy, 78(4), 310-319.
  29. Thompson SJ, Cochran G, Barczyk A (2012). Family functioning and mental health in runaway youth: association with posttraumatic stress symptoms. Journal of traumatic stress, 25(5), 598-601. (Read full article)
  30. Cochran G, Field C, Foreman M, Ylioja T, Brown C (2016). Effects of brief intervention on subgroups of injured patients who drink at risk levels. Injury prevention, 22(3), 221-5. (Read full article)
  31. Cochran G, Field C, Caetano (2015). Changes in Classes of Injury-Related Risks and Consequences of Risk-Level Drinking: a Latent Transition Analysis. The journal of behavioral health services & research, 42(3), 355-66. (Read full article)
  32. Knowlton AR, Weir B, Fields J, Cochran G, McWilliams J, Wissow L, Lawner B (2016). Pediatric Use of Emergency Medical Services: The Role of Chronic Illnesses and Behavioral Health Problems. Prehospital emergency care, 20(3), 362-8. (Read full article)
  33. Cochran G, Gordon AJ, Gellad WF, Chang CH, Lo-Ciganic WH, Lobo C, Cole E, Frazier W, Zheng P, Kelley D, Donohue J (2017). Medicaid prior authorization and opioid medication abuse and overdose. The American journal of managed care, 23(5), e164-e171. (Read full article)
  34. Parrish DE, von Sternberg K, Velasquez MM, Cochran G, Sampson M, Mullen P (2012). Characteristics and factors associated with the risk of a nicotine exposed pregnancy: expanding the CHOICES preconception counseling model to tobacco. Maternal and child health journal, 16(6), 1224-31. (Read full article)
  35. Ylioja T, Cochran G, Woodford MR, Renn K (2018). Frequent Experience of LGBQ Microaggression on Campus Associated With Smoking Among Sexual Minority College Students. Nicotine & tobacco research, 20(3), 340-346. (Read full article)
  36. Cochran G, Rosen D, McCarthy RM, Engel R (2017). Risk Factors for Symptoms of Prescription Opioid Misuse: Do Older Adults Differ from Younger Adult Patients?. Journal of gerontological social work, 60(6-7), 443-457. (Read full article)
  37. Rosen D, Engel RJ, Beaugard C, Davis N, Cochran (2019). Baby Boomer's Substance Abuse and Researcher Indifference. Journal of gerontological social work, 62(1), 16-28. (Read full article)
  38. Roby J, Cochran (2007). Child headed households in Mozambique: Towards needs-based policy and practice. Social development issues, 29(3), 19-32.
  39. Cochran G, Field C, Caetano (2014). Injury-related consequences of alcohol misuse among injured patients who received screening and brief intervention for alcohol: a latent class analysis. Substance abuse, 35(2), 153-62. (Read full article)
  40. Cochran G, Woo B, Lo-Ciganic WH, Gordon AJ, Donohue JM, Gellad W (2015). Defining Nonmedical Use of Prescription Opioids Within Health Care Claims: A Systematic Review. Substance abuse, 36(2), 192-202. (Read full article)
  41. Ylioja T, Cochran G, Chang Y, Tindle HA, Rigotti N (2017). Postdischarge smoking cessation in subgroups of hospitalized smokers: A latent class analysis. Substance abuse, 38(4), 493-497. (Read full article)
  42. Cochran G, Pacella M, Ringwald W, Repine M, Hruschak V, Beaugard C, Sewall C, Rosen D, Alarcon LH, Tarkin IS, Moloney GB, Corcos (2019). Opioid use patterns and risk characteristics among injured patients. Substance abuse, 41(1), 24-28.
  43. Hruschak V, Hildebrand A, Cochran G (2019). Psychiatric Comorbidity and Co-occurring Opioid Misuse: Depression Mediates the Relationship between Post-Traumatic Stress Disorder and Opioid Misuse in Community Pharmacy Settings. Substance abuse, 41(1), 77-84.
  44. Lobo C, Cochran G, Chang J, Gellad W, Gordon AJ, Jalal H, Ciganic J, Kelley D, Donohue J (2019). Associations between the specialty of opioid prescribers and opioid addiction, misuse and overdose outcomes. Pain medicine (Malden, Mass.), 21(9), 1871-1890.
  45. Cochran G, Bacci JL, Ylioja T, Hruschak V, Miller S, Seybert AL, Tarter (2016). Prescription opioid use: Patient characteristics and misuse in community pharmacy. Journal of the American Pharmacists Association, 56(3), 248-256.e6. (Read full article)
  46. Cochran G, Field C, Karp J, Seybert AL, Chen Q, Ringwald W, Hruschak V, Chickering S, Kincman J, Jaber A, Tarter (2018). A community pharmacy intervention for opioid medication misuse: A pilot randomized clinical trial. Journal of the American Pharmacists Association, 58(4), 395-403. (Read full article)
  47. Ylioja T, Reddy V, Ambrosino R, Davis EM, Douaihy A, Slovenkay K, Kogut V, Frenak B, Palombo K, Schulze A, Cochran G, Tindle H (2017). Using Bioinformatics to Treat Hospitalized Smokers: Successes and Challenges of a Tobacco Treatment Service. Joint Commission journal on quality and patient safety, 43(12), 621-632. (Read full article)
  48. Cochran G, Smid M, Krans EE, Bryan MA, Gordon AJ, Lundahl B, Silipigni J, Haaland B, Tarter T (2019). A Pilot Multisite Study of Patient Navigation for Pregnant Women with Opioid Use Disorder . Contemporary clinical trials, 87, 105888.
  49. Lo-Ciganic WH, Huang J, Zhang HH, Weiss J, Kwoh K, Donohue J, Gordon A, Cochran G, Malone D, Kuza C, Gellad W (2020). Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study. PloS one, 15(7), e0235981.
  50. Hruschak V, Cochran G, Wasan (2019). Psychosocial interventions for chronic pain and comorbid opioid misuse: a narrative review of the literature. Journal of opioid management, 14(5), 345-358.
  51. Bhardwaj SB, Cochran G, Kmiec (2019). Opioid overdose history and awareness of naloxone in patients seeking outpatient detoxification. Journal of opioid management, 15(3), 253-259. (Read full article)
  52. Hruschak V, Cochran G, Wasan A (2018). Psychosocial interventions for chronic pain and comorbid prescription opioid use disorders: A narrative review of the literature. Journal of opioid management, 14(5), 345-358. (Read full article)
  53. Hruschak V, Cochran (2018). Psychosocial predictors in the transition from acute to chronic pain: a systematic review. Psychology, health & medicine, 23(10), 1151-1167. (Read full article)
  54. Cochran G, Gordon AJ, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter (2016). Developing a framework of care for opioid medication misuse in community pharmacy. Research in social & administrative pharmacy, 12(2), 293-301. (Read full article)
  55. Cochran G, Hruschak V, Bacci JL, Hohmeier KC, Tarter (2017). Behavioral, mental, and physical health characteristics and opioid medication misuse among community pharmacy patients: A latent class analysis. Research in social & administrative pharmacy, 13(6), 1055-1061. (Read full article)
  56. Cochran G, Field C, Lawson (2015). Pharmacists Who Screen and Discuss Opioid Misuse With Patients: Future Directions for Research and Practice. Journal of pharmacy practice, 28(4), 404-12. (Read full article)
  57. Cochran GT, Engel RJ, Hruschak VJ, Tarter R (2017). Prescription Opioid Misuse Among Rural Community Pharmacy Patients: Pilot Study for Screening and Implications for Future Practice and Research. Journal of pharmacy practice, 30(5), 498-505. (Read full article)
  58. Cochran G, Roll J, Jackson R, Kennedy (2014). Health care reform and the behavioral health workforce. Journal of social work practice in the addictions, 14(2), 127-40.
  59. Cochran G, Stitzer M, Nunes EV, Hu MC, Campbell (2014). Clinically relevant characteristics associated with early treatment drug use versus abstinence. Addiction science & clinical practice, 9, 6. (Read full article)
  60. Cochran G, Cole E, Warwick J, Donohue J , Gordon A, Gellad W, Bear T, Kelley D, DiDomenico E, Pringle (2019). Rural Access to MAT in Pennsylvania (RAMP): A Hybrid Implementation Study Protocol for Medication Assisted Treatment Adoption among Rural Primary Care Providers. Addiction science & clinical practice, 14(1), 25.
  61. Bryan MA, Smid M, Cheng M, Fortenberry K, Kenney A, Muniyappa B, Pendergrass D, Gordon A, Cochran, G (2020). Perinatal care and medication for opioid use disorder (MOUD) in rural Utah: A study protocol. Addiction science & clinical practice, 15(33), 1-14.
  62. Cochran G, Field, (2013). Brief intervention and social work: a primer for practice and policy. Social work in public health, 28(3-4), 248-263.
  63. Cochran G, Rubinstein J, Bacci JL, Ylioja T, Tarter (2015). Screening Community Pharmacy Patients for Risk of Prescription Opioid Misuse. Journal of addiction medicine, 9(5), 411-6. (Read full article)
  64. Gordon AJ, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Kelley D, Donohue J (2015). Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program. Journal of addiction medicine, 9(6), 470-7. (Read full article)
  65. Suffoletto B, Yanta J, Kurtz R, Cochran G, Douaihy A, Chung (2017). Acceptability of an Opioid Relapse Prevention Text-message Intervention for Emergency Department Patients. Journal of addiction medicine, 11(6), 475-482. (Read full article)
  66. Cochran GT, Hruschak V, Abdullah W, Krans E, Douaihy AB, Bobby S, Fusco R, Tarter (2018). Optimizing Pregnancy Treatment Interventions for Moms (OPTI-Mom): A Pilot Study. Journal of addiction medicine, 12(1), 72-79. (Read full article)
  67. Cochran G, Field C, Lawson K, Erickson (2013). Pharmacists' Knowledge, Attitudes, and Beliefs Regarding Screening and Brief Intervention for Prescription Opioid Abuse: A Survey of Utah and Texas Pharmacists. Journal of pharmaceutical health services research, 4, 71-9.
  68. Field CA, Cochran G, Caetano R, Foreman M, Brown C (2014). Postdischarge nonmedical use of prescription opioids in at-risk drinkers admitted to urban level I trauma centers. The journal of trauma and acute care surgery, 76(3), 833-9. (Read full article)
  69. Hohmeier K, Cernasev A, Sensmeier M, Hall E, Webb K, Barenie R, Cochran (2021). U.S. Student Pharmacist Perceptions of the Pharmacists Role in Methadone for Opioid Use Disorder: A Qualitative Study. SAGE open medicine, 9, 1-7.
  70. Cochran G, Lo-Ciganic WH, Gellad WF, Gordon AJ, Cole E, Lobo C, Frazier W, Zheng P, Chang CH, Kelley D, Donohue J (2018). Prescription Opioid Quality Measures Applied Among Pennsylvania Medicaid Enrollees. Journal of managed care & specialty pharmacy, 24(9), 875-885. (Read full article)
  71. Cochran G, Hruschak V, DeFosse B, Hohmeier K (2016). Prescription opioid abuse: pharmacists' perspective and response. Integrated pharmacy research & practice, 5, 65-73. (Read full article)
  72. Lindley B, Cox N, Cochran G (2019). Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: A review. Integrated pharmacy research & practice, 8, 85-96.
  73. Bryan MA, Charron E, Adeoye-Olatunde O, Brown J, Ghitza U, Winhusen TJ, Cochran (2021). Concomitant cannabis misuse and associations with depression, pain and substance misuse among patients prescribed opioids. Pharmacy (Basel, Switzerland), 9(3), 134.
  74. Cochran G, Montgomery K, Rubin (2010). Does evidence-based practice influence state legislators¿ decision-making process? An exploratory study. Journal of policy practice, 9(3), 263-83.
  75. Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad W (2019). Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA network open, 2(3), e190968. (Read full article)
  76. Cochran (2010). Social policy advocacy evaluation: A more complete model for social work. Professional development (Philadelphia, Pa.), 13(1), 27-39.
  77. Cochran G, Landuyt (2010). A survey of continuing education programs conducted by Professional Development: The International Journal of Continuing Social Work Education. Professional development (Philadelphia, Pa.), 13(2), 55-72.
  78. Tarter RE, Cochran G, Reynolds (2018). Prevention of Opioid Addiction. 20(1), 38-60.
  79. Cochran (2005). Investigation of child headed households in Mozambique, Africa.
  80. Brown JL, Cochran G, Bryan MA, Charron E, & Winhusen T (2022). Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids. Substance abuse, 43(1), 1110-1115.
  81. Charron E, White A, Carlston K, Abdullah W, Baylis JD, Pierce S, Businelle MS, Gordon AJ, Krans EE, Smid MC, Cochran (2023). Prospective Acceptability of Digital Phenotyping among Pregnant and Parenting People with Opioid Use Disorder: A Multisite Qualitative Study. Frontiers in psychiatry,
  82. Smid MC, Charron E, AA Allshouse AA, Campbell K, Metz TD, Debbink MP, Cochran (2023). Co-occurring opioid and methamphetamine use disorder and severe maternal morbidity and mortality in Utah. . American journal of obstetrics & gynecology MFM,
  83. Hohmeier KC, Cernasev A, Leibold C, Moore TM, Schlesinger E, Arce I, Geminn W, Chisholm-Burns M, Cochran G (2024). Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment. Exploratory research in clinical and social pharmacy, 12,
  84. McLeman B; Gauthier P; Lester LS; Homsted F; Gardner V; Moore SK; Joudrey PJ; Saldana L; Cochran G; Harris J; Hefner K; Chongsi E; Kramer K; Vena A; Ottesen R; Gallant T; Boggis J; Rao D; Page M; Cox N; Iandiorio M; Ambaah E; Ghitza E; Fiellin DA; Marsch L (2024). Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder in Primary Care: Study Design and Methodological Considerations. Addiction science & clinical practice, 19(1),
  85. Hafen K, Wallace H, Fritz K, Fordham C, Haskell T, Kelley AT, Jones AL, Cochran G, Gordon AJ (2024). A novel rural hospital/clinic-system practice-based research network: the rural addiction implementation network (RAIN) initiative and its goals, implementation, and early results. The American journal of drug and alcohol abuse,
  86. Seliski N, Madsen T, Eley E, Colosimo J, Engar E, Gordon A, Barnett G, Humiston G, Morsillo T, Stolebarger L, Smid MC, Cochran (2024). Implementation of a Rural Emergency Department-Initiated Buprenorphine Program in the Mountain West: A Study Protocol. Addiction science & clinical practice,
  87. Smid, MC, Seliski N, Charles JE, Castro S, Humiston E, Cash E, Allshouse A, Turner E, Carlston K, Gibson M, Gordon AJ, Cochran G (2024). Prevention of postpartum methamphetamine use with micronized progesterone trial (PROMPT): A pilot randomized controlled trial protocol. Contemporary clinical trials communications,
  88. Cochran G, Brown J, Yu Z, Gordan A, Frede S, Hardy C, Castora-Binkley M, Homested F, Marsch L, Holtyn A, Winhusen T (2024). CTN-0138: Adaptation, Implementation, and Cluster Randomized Trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool—A Protocol Paper. Addiction science & clinical practice,
  89. Franks L, Cochran G, Reeves C, Incze MA, Hardy CJ, Gordon AJ, Kelley AT (2024). Evaluations of state medical cannabis programs in the US: A narrative review. . Medical cannabis and cannabinoids,
  90. Nguyen K, Wilson DL, Diiulio J, Hall B, Militello L, Gellad WF, Harle CA, Lewis M, Schmidt S, Rosenberg EI, Nelson D, He X, Wu Y, Bian J, Staras SAS, Gordon AJ, Cochran G, Kuza C, Yang S, Lo-Ciganic W (2024). Design and development of a machine-learning-driven opioid overdose risk prediction tool integrated in electronic health records in primary care settings. Bioelectronic medicine, 18(10),
  91. Song K, Amuan M, Adams R, Kennedy E, Gordon AJ, Carlson K, Pogoda T, Meyer E, Cochran G, Spevak C, Pugh M (2024). Diagnosis of Alcohol Use Disorder and Deaths Related to Alcohol, Drug Overdose, or Suicide among Post-9/11 Active Duty Service Members and Veterans Following Traumatic Brain Injury. Journal of addiction medicine,
  92. Hardy, C., Jaggers, J., Lundahl, B., Gass, M., Osteen, P, & Cochran, G (2024). Perceptions of youth transport in wilderness therapy. Residential treatment for children & youth,
  93. Hruschak VJ, Yuan Y, Ringwald W, Beaugard C, Repine M, Pacella-LaBarbara M, Rosen D, Cochran (2021). Pain Appraisals in Patients with Physical Injury: Assessing the Role of Distress Tolerance in the Relationship between Depression and Pain Catastrophizing. Health & social work, 46(3), 187-198. (Read full article)
  94. Hruschak V, Rosen D, Tierney M, Eack SM, Wasan AD, Cochran (2021). Integrated Psychosocial Group Treatment: A Randomized Pilot Trial of a Harm Reduction and Preventive Approach for Patients with Chronic Pain at Risk of Opioid Misuse. Pain medicine (Malden, Mass.), 22(9), 2007-2018. (Read full article)
  95. Cochran G, Cole ES, Sharbaugh M, Nagy D, Gordon AJ, Gellad WF, Pringle J, Bear T, Warwick J, Drake C, Chang CH, DiDomenico E, Kelley D, Donohue (2022). Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder. Journal of addiction medicine, 16(2), e87-e96. (Read full article)
  96. Magel JJ, Cochran G, West N, Fritz JM, Bishop MD, Gordon A (2022). Physical therapists' attitudes are associated with their confidence in and the frequency with which they engage in prescription opioid medication misuse management practices with their patients. A cross-sectional study. Substance abuse, 43(1), 433-441. (Read full article)
  97. Kelley AT, Smid MC, Baylis JD, Charron E, Binns-Calvey AE, Archer S, Weiner SJ, Begaye LJ, Cochran (2021). Development of an unannounced standardized patient protocol to evaluate opioid use disorder treatment in pregnancy for American Indian and rural communities. Addiction science & clinical practice, 16(1), 40. (Read full article)
  98. Magel J, Bishop MD, Lonnemann E, Cochran G, Fritz JM, West N, Gordon A (2022). The association between advanced orthopedic certification and confidence and engagement in prescription opioid medication misuse management practices: a cross-sectional study. The Journal of manual & manipulative therapy, 30(4), 228-238. (Read full article)
  99. Carter G, Yu Z, Aryana Bryan M, Brown JL, Winhusen T, Cochran (2022). Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST). Addictive behaviors, 126, 107178. (Read full article)
  100. Kelley AT, Smid MC, Baylis JD, Charron E, Begaye LJ, Binns-Calvey A, Archer S, Weiner S, Pettey W, Cochran (2022). Treatment access for opioid use disorder in pregnancy among rural and American Indian communities. Journal of substance abuse treatment, 136, 108685. (Read full article)
  101. Baylis JD, Charron E, Archer S, Garets M, Bryan MA, Foringer J, Kelley AT, Smid MC, Cochran (2022). Attitudes, self-efficacy, and practices related to opioid risk assessment and mitigation: A comparison of health care professionals in rural communities. Substance abuse, 43(1), 1163-1171. (Read full article)
  102. Bryan MA, Mallik D, Cochran G, Lundahl (2022). Mindfulness and Savoring: A Commentary on Savoring Strategies and Their Implications for Addiction Treatment. Substance use & misuse, 57(5), 822-826. (Read full article)
  103. Guo J, Gellad WF, Yang Q, Weiss JC, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Kuza CC, Wilson DL, Lo-Ciganic W (2022). Changes in predicted opioid overdose risk over time in a state Medicaid program: a group-based trajectory modeling analysis. Addiction (Abingdon, England), 117(8), 2254-2263. (Read full article)
  104. Cochran G, Charron E, Brown JL, Cernasev A, Hohmeier KC, Winhusen T (2022). Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study. Drug and alcohol dependence, 234, 109406. (Read full article)
  105. Lo-Ciganic WH, Donohue JM, Yang Q, Huang JL, Chang CY, Weiss JC, Guo J, Zhang HH, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Wilson DL, Kuza CC, Gellad W (2022). Developing and validating a machine-learning algorithm to predict opioid overdose in Medicaid beneficiaries in two US states: a prognostic modelling study. The Lancet. Digital health, 4(6), e455-e465. (Read full article)
  106. Charron E, Okifuji A, Bryan MA, Reese S, Brown JL, Ferguson A, Ghitza UE, Winhusen T, Cochran (2022). Pain Severity and Interference and Substance Use Among Community Pharmacy Patients Prescribed Opioids: A Secondary Analysis of the PHARMSCREEN Study. The journal of pain, 23(8), 1448-1459. (Read full article)
  107. Cochran G, Shen J, Cox N, Field C, Carlston K, Sengpraseut B, White A, Okifuji A, Jackman C, Haaland B, Ragsdale R, Gordon AJ, Tarter (2022). Addressing opioid medication misuse at point of service in community pharmacy: A study protocol for an interdisciplinary behavioral health trial. Contemporary clinical trials, 116, 106759. (Read full article)
  108. Smid MC, Allshouse AA, McMillin GA, Nunez K, Cavin T, Worden J, Buchi K, Muniyappa B, Varner MW, Cochran G, Metz T (2022). Umbilical Cord Collection and Drug Testing to Estimate Prenatal Substance Exposure in Utah. Obstetrics and gynecology, 140(2), 153-162. (Read full article)
  109. Kraemer KL, Althouse AD, Salay M, Gordon AJ, Wright E, Anisman D, Cochran G, Fischer G, Gellad WF, Hamm M, Kern M, Wasan A (2022). Effect of Different Interventions to Help Primary Care Clinicians Avoid Unsafe Opioid Prescribing in Opioid-Naive Patients With Acute Noncancer Pain: A Cluster Randomized Clinical Trial. JAMA health forum, 3(7), e222263. (Read full article)
  110. Cloutier RM, Cole ES, McDonough BL, Lomauro DA, Miller JP, Talbert AL, Bear TM, Bridges NC, Foulds AL, Taber R, Gordon AJ, Cochran GT, Kmiec J, Donohue JM, Kelley D, DiDomenico E, Adair D, Pringle J (2023). Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model. Implementation research and practice, 4, 26334895231152808. (Read full article)
  111. Charles JE, Baylis J, Smid MC, Cochran (2023). Nonfatal Overdoses Among Pregnant Individuals With Opioid Use Disorder. Obstetrics and gynecology, 141(5), 961-963. (Read full article)
  112. Charron E, Yu Z, Lundahl B, Silipigni J, Okifuji A, Gordon AJ, Baylis JD, White A, Carlston K, Abdullah W, Haaland B, Krans EE, Smid MC, Cochran (2023). Cluster analysis to identify patient profiles and substance use patterns among pregnant persons with opioid use disorder. Addictive behaviors reports, 17, 100484. (Read full article)
  113. Hohmeier KC, Cernasev A, Leibold C, Moore TM, Schlesinger E, Cochran G, Arce I, Geminn W, Chisholm-Burns (2023). Community-Centered Patient Journey Map in Opioid Use Disorder: A Tool to Address Compassion Fatigue among Community Pharmacists. Pharmacy (Basel, Switzerland), 11(2), (Read full article)
  114. Charron E, Brooks JH, Peterson KT, Akinwolere OG, Winhusen T, Cochran (2023). Mapping prescription drug monitoring program data to self-report measures of non-medical prescription opioid use in community pharmacy settings. Research in social & administrative pharmacy, 19(8), 1171-1177. (Read full article)
  115. Magel J, Hartman P, Fritz JM, Koch NN, Dostal H, Vollmer N, Ferguson NL, Tapken J, Cohee K, Cochran G, Gordon A (2023). Patients' Perceptions of Physical Therapists Addressing Opioid Misuse. Substance abuse, 44(1), 32-40. (Read full article)
  116. Cernasev A, Hohmeier K, Field C, Gordon AJ, Elliott S, Carlston K, Broussard G, Cochran (2023). Co-use of Opioid Medications and Alcohol Prevention Study (COAPS). Substance abuse, 44(3), 130-135. (Read full article)
  117. Bridges NC, Taber R, Foulds AL, Bear TM, Cloutier RM, McDonough BL, Gordon AJ, Cochran GT, Donohue JM, Adair D, DiDomenico E, Pringle JL, Gellad WF, Kelley D, Cole E (2023). Medications for opioid use disorder in rural primary care practices: Patient and provider experiences. Journal of substance use and addiction treatment, 154, 209133. (Read full article)
  118. Jarrett JB, Bratberg J, Burns AL, Cochran G, DiPaula BA, Legreid Dopp A, Elmes A, Green TC, Hill LG, Homsted F, Hsia SL, Matthews ML, Ghitza UE, Wu LT, Bart (2023). Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. Substance abuse, 44(4), 264-276. (Read full article)
  119. Cochran G, Smid MC, Krans EE, Yu Z, Carlston K, White A, Abdulla W, Baylis J, Charron E, Okifugi A, Gordon AJ, Lundahl B, Silipigni J, Seliski N, Haaland B, Tarter (2024). Patient navigation for pregnant individuals with opioid use disorder: Results of a randomized multi-site pilot trial. Addiction (Abingdon, England), 119(3), 544-556. (Read full article)
  120. Pugh MJ, Haun JN, White PJ, Cochran G, Mohanty AF, McAndrew LM, Gordon AJ, Nelson RE, Vanneman ME, Naranjo DE, Benzinger RC, Jones AL, Kean J, Zickmund SL, Fagerlin (2024). Developing Evidence to Support Policy: Protocol for the StrAtegic PoLicy EvIdence-Based Evaluation CeNTer (SALIENT). JMIR research protocols, 13, e59830. (Read full article)
  121. Broussard G, Hohmeier K, Field C, Gordon AJ, Carlston K, Cernasev A, Tyszko M, Snyder A, Cochran G (2024). Barriers and Facilitators to the Implementation of Screening and Intervention for Co-use Opioid Medications and Alcohol among Community Pharmacy Patients. . Journal of substance abuse treatment,
  122. Kinsey K, Broussard G, Wei Y, Field G, Cox N, White A, Hohmeier K, Cochran (2025). Exploratory Analysis of Pharmacist Involvement in Motivational Interviewing Intervention for Patients with Prescription Opioid Misuse Behaviors. Journal of the American Pharmacists Association Practice Innovations,
  123. Reeves C, Franks L, Kelley AT, Incze M, Gordon AJ, Yu Z, Flake E, Cochran (2025). Understanding Motives for Illicit Medicinal Cannabis Use: An Exploratory Analysis in a Medical Cannabis Program. Journal of cannabis research,
  124. Winhusen TJ, Kropp F, Smid, MC, Young JL, Davies TH, Lewis D, Rosa C, Dilawar M, Krans EE, Hodgkins C, Cochran G, & Lofwall M (2025). Personally-tailored opioid-overdose and medication for opioid use disorder (MOUD) education (TOME) significantly increases MOUD and overdose knowledge in peripartum individuals: Results from a randomized controlled pilot trial. . Drug and alcohol dependence,
  125. Hohmeier KC, Broussard G, Tyszko M, Barland K, Carlston K, Wei Y, Field C, Gordon AJ, Cernasev A, Cochran G (2025). Impact of community pharmacists on reducing opioid and alcohol co-use: a pilot randomized control trial of a medication therapy management intervention. . Journal of the American College of Clinical Pharmacy,
  126. Cash E, Cochran G, Smid M, Charles J, Humiston G, Wei Y, Mauerman N, Carlston K, Broussard G, Sengpraseut B, Martin P, Winhusen T (2025). Overdose risk profiles in pregnancy: Latent class analysis of pregnant individuals with opioid use disorder. . Journal of substance abuse treatment,
  127. Witcraft SM, Holcomb L, Wei Y, Cochran G, Winhusen TJ, Lofwall MR, Martin PR, Young JL, Spinali, J, Guille (2025). Factors associated with opioid-involved overdose: Descriptive data from a randomized controlled trial evaluating extended-release buprenorphine for perinatal opioid use disorder. Substance use & addiction journal,
  128. Impact of a brief personally tailored opioid-overdose and medication for opioid use disorder education intervention on naloxone acceptance in peripartum individuals: A secondary exploratory analysis (2025). Lofwall MR, Kropp F, Charles J, Cochran G, Douaihy A, Edwards M, Lewis D, Rosa C, Young JL, Winhusen TJ. Journal of substance use and addiction treatment,
  129. Magel JS, Siantz E, Incze MA, Beneciuk JM, Fritz JM, Kelley AT, Cochran G, Blosser P, Hartman P, Tyszko M, Kertesz S, Gordon A (2025). Primary care provider attitudes regarding physical therapists addressing opioid use and opioid misuse: A qualitative study. Physical Therapy & Rehabilitation Journal,
  130. Wilson DL, Nguyen K, Gellad WF, Hong JJ, Diiulio J, Militello L, Yan S, Harle CA, Nelson D, Rosenberg EI, Schmidt S, Chang CH, Cochran G, Wu Y, Staras SAS, Kuza C, Lo-Ciganic W (2025). Protocol for a Single-Arm Pilot Clinical Trial: Developing and Evaluating a Machine-Learning Opioid Prediction & Risk-Stratification E-Platform (DEMONSTRATE). Journal of Clinical Medicine,
  131. Faysal JA, Lo-Ciganic W, Gellad WF, Wu Y, Harle CA, Nguyen K, Huang JL, Cochran G, Wilson DL, Staras SAS, Schmidt SOF, Rosenberg EI, Nelson D, Yan S, Reisfield GM, Greene WM, Kuza C, Hasan MM (2025). Developing and validating a machine learning algorithm to predict the risk of incident opioid use disorder among OneFlorida+ patients: a prognostic modeling study. . Journal of medical Internet research,
  132. Charron E, Allshouse AA, Tak C, Campbell KA, Gordon AJ, Cochran G, Smid M (2026). Treatment of opioid use disorder in pregnancy among individuals with and without co-occurring stimulant use disorder: A retrospective cohort study. Journal of substance use and addiction treatment,
  133. Snyder A, Math S, Campbell K, Schiff D, Wheeler A, Carlston K, Gordon A, Winhusen TJ, Cochran G, Smid MC (2025). Protocol Commentary for the SUCCESS (Successful Recruitment and Retention in a Randomized Controlled Trial of Pregnant Participants with Opioid Use Disorder) Study. Subst Use Addctn J .,
  134. D¿Onofrio G, Herring AA, Hawk KF, Perrone J, Cowan E, McCormack RP, Dziura J, Matthews AG, Pantalon MV, Owens P, Martel S, Coupet E Jr, Lofwall MR, Walsh SL, Edelman EJ, Carpenter JE, Strout TD, Baumann MR, Anderson E, Barrett TW, Dorey A, Taillac P, Cochran G, Crandall CS, Wilson J, Manteuffel J, Cole JB, Whiteside LK, Jones C, Samuels E, Huntley K, Fiellin D (2026). Emergency Department–Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. . JAMA,
  135. Cochran G, Broussard G, Wei Y, Field C, Gordon AJ, Hohmeier KC (2026). A short communication of pain outcomes following a pharmacist-delivered alcohol and opioid use reduction intervention. Drug Alcohol Depend Rep. . Drug and alcohol dependence reports,

Book Chapter

  1. Gordon AJ, Cochran G, Smid MC, Manhapra A, Kertesz S (2020). Prescribing, prescription monitoring, and health policy.
  2. Cochran G, Ylioja (2016). Drug Use and Minority Health in the US: Prevalence, Causes, and Future Directions.
  3. Cochran G, Thompson S (2012). Alcohol Abuse Prevention and Treatment in Health Care Settings: Screening and Brief Intervention. 55-78.
  4. Bryan MA, Hruschak V, Dennis C, Rosen D, Cochran (2020). The Opioid Crisis.

Commentary

  1. Garets M, Arther S, Kitchens C, Cochran G, Gordon AJ (2019). The 2019 Addiction Health Services Research Conference: Insights, Review, and Abstracts. Under review, . Substance abuse, 40(4), 469-472.
  2. White A, Lundahl B, Bryan MA, Okifuji, Smid A, Gordon A, Carlston K, Silipigni J, Abdullah W, Krans E, Kenney A, Cochran G (2021). Pregnancy and the opioid crisis: Heightened effects of COVID-19. Journal of addiction medicine,
  3. Cox N, Hohmeier KC, Cernasev A, Field C, Elliott S, LaFleur G, Barland KM, Green M, Gardner JW, Gordon AJ, Cochran G (2024). Engaging community pharmacies in practice-based research: lessons from opioid-focused research. Research in Social and Administrative Pharmacy,

Book Review

  1. Cochran (2011). Book Review. 21, 121-4.

Editorial

  1. Cochran G, Bruneau J, Cox N, Gordon A (2020). Medication Treatment for Opioid Use Disorder and Community Pharmacy: Expanding Care During a National Epidemic and Global Pandemic. 41(3), 269-274.

Letter

  1. Aruri M, Cochran G, Pringle (2020). Role of pharmacists in the opioid use disorder (OUD) crisis. Research in social & administrative pharmacy, 2, 228-229.
  2. Gordon A, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Donohue J (2016). Treatment Quality for Buprenorphine Care: The Pot at the End of the Rainbow. Journal of addiction medicine, 10(3), 210-1. (Read full article)
  3. Cochran G, Brown J, Winhusen (2024). Letter to Editor responding to “Paths Forward for Clinicians Amidst the Rise of Unregulated Clinical Decision Support Software: Our Perspective on NarxCare. Journal of general internal medicine,

Abstract

  1. Parrish DE, von Sternberg K, Cochran G, Sampson M, Mullen P, Velasquez M (2009). Alcohol and nicotine exposed pregnancies: Common and unique characteristics associated with risk. 33(6), 344A-344A.
  2. Field C, Cochran G, Caetano (2012). The role of drug use in brief alcohol interventions: A multi-ethnic/racial analysis. 7(Suppl 1), A18.
  3. Cochran G, Rubinstein J, Bacci J, Ylioja T, Tarter (2016). Community pharmacy and opioid pain medication: Screening patients who misuse or are at risk for misuse; also presented orally at the Association for Medical Education and Research in Substance Abuse 39th National Conference, Washington, DC. 37(2), 46A.
  4. Cochran G, Gordon A, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter (2016). A continuum of care model for opioid misuse in community pharmacy; also presented orally at the Association for Medical Education and Research in Substance Abuse 39th National Conference, Washington, DC. 37(2), 47A.
  5. Cochran G, Woo B, Lo-Ciganic WH, Gordon A, Donohue J, Wei-Hsuan L, Gellad (2015). Defining non-medical use of prescription opioids within health care claims: A systematic review; also presented orally at the Association for Medical Education and Research in Substance Abuse 38th National Conference, San Francisco, CA. 36(2), 67A.
  6. Cochran G, Field C, Foreman M, Brown (2015). Effects of brief Intervention on subclasses of injured patients who rink at risk levels; also presented orally at the Association for Medical Education and Research in Substance Abuse 38th National Conference, San Francisco, CA. 36(2), 75A.
  7. Cochran G, Brodie B, Bell A, Bennett (2015). Factors associated with opioid overdose resuscitation; also presented orally at the Association for Medical Education and Research in Substance Abuse 38th National Conference, San Francisco, CA. 36(2), 48A.
  8. Cochran G (2011). Latent predictors of change from screening and brief alcohol interventions: A mixture modeling approach; also presented orally at the Texas Research Society on Alcoholism Annual Scientific Meeting, Lubbock, TX. 35(6), 337A-337A.
  9. Cochran, G. Lo-Ciganic, W-H., Gellad, W., Gordon, A.J., Cole, E., Lobo, C., Frazier, W., Zheng, P., Kelley, D., & Donohue, J.M (2018). Quality Measures of Prescription Opioid Utilization in a Large State Medicaid Program.
  10. Sakai, H., Hruschak, V., Cochran, G., & Copeland, V (2018). Virtual Reality-Based Training for Screening, Brief Intervention, and Referral to Treatment in Social Work Education.
  11. Smid M, Charles J, Cavin T, Cochran G, Varner M, Gordon A (2020). Takes Two to Make Three: Pregnant Women With Substance Use Disorder's Intentions for Partner's Role . 135(59S),
  12. Hafen K, Smid M, Garets M, Machado A, White A, Cochran (2021). Motivations for Recovery among Pregnant Individuals with Opioid Use Disorder.
  13. Hafen, K. L., Smid, M., Garets, M., Machado, A., White, A. H., & Cochran, G (2022). Motivations for Recovery Among Pregnant Individuals With Opioid Use Disorder. 139, 53s-54s.
  14. Cochran G, Vanneman M, Gulbransen S, Ransco M, Curtis R, Killam K, Rohm, (2024). Addressing Racial and Ethnic Disparities through Enhancement of Data Quality. .

Other

  1. Cochran (2010). The Promise and Pitfalls of Organizational Change. 28(4), 7-11.

Report

  1. Rosen D, Brusoski M, Engel R, Cochran G (2018). The Integrated Health Care Training Corps: Corps: A collaboration between the University of Pittsburgh School of Social Work and the UPMC Health Plan: Year 3 Report.
  2. Donohue J, Cole E, Kim JY, Zheng P, Lo-Ciganic W-H, Gordon A, Gellad A, Cochran (2017). Report on Opioid Prescribing Quality Measures, Opioid Use, Opioid Use Disorder, and Medication-Assisted Treatment in Pennsylvania Medicaid: 2013-2015.
  3. Cochran G, Ylioja T, Fisher (2015). Treatment Guide: Targeted medication therapy management for prescription opioid misuse.
  4. Donohue J, Cochran G, Gordon A, Zemaitis M, Gellad (2013). Report on Opioid Use Disorder and Buprenorphine Use in Pennsylvania Medicaid.
  5. Cochran (2010). The Use of the SEE Data in Texas: The Case of the Texas Parks and Wildlife Department.
  6. Cochran (2010). The Use of the SEE Data in Texas: The Case of the University of Texas at San Antonio.
  7. Cochran G, Landuyt (2010). The Second Annual Survey of Continuing Education Programs Conducted by Professional Development: The International Journal of Continuing Social Work Education.
  8. Fong R, Urban B, Cochran (2008). Evaluation of south Texas coalition against human trafficking (STCAHT).
  9. Fong R, Urban B, Cochran (2008). Evaluation of Catholic Charities of San Antonio's human trafficking trainings and presentations.
  10. McRoy R, Ayers-Lopez S, Wallace M, Fong R, Schwartz A, Leonardo A, Simons O, Popham A, Wheeler K, Boyd K, Edwards E, Tostada B, Holmes T, Cochran G, Kim S, Steinley-Bungarner M, Naik R, Cody P, Barczyk A, Burt (2008). Adoptive and foster couples retreat and support network program report: Part two.
  11. Cochran (2008). CHIP: A Utah success story.
  12. McRoy R, Ayers-Lopez S, Wallace M, Fong R, Schwartz A, Leonardo A, Simons O, Popham A, Wheeler K, Boyd K, Edwards E, Tostada B, Holmes T, Cochran G, Kim S, Steinley-Bungarner M, Naik R, Cody P, Barczyk A, Burt (2008). Adoptive and foster couples retreat and support network program report 2007-2008.
  13. Harris N, Frost CJ, Lundahl B, Yaffe J, Cochran G, Moran M, Smith (2005). Salt Lake City Weed and Seed: Final report.
  14. DiDomenico E, Kelley D, Cole E, Pringle J, Warwick J, Donohue J, Gellad W, Cochran G, Kmic J, Bear T, Chang J, Kim JY, Gordon A (2018). Project Rural Access to MAT in Pennsylvania (RAMP): Mid-Grant Report.
  15. Archer S, Bryan MA, Garets M, Baylis JB, Charron E, Kelley AT, Foringer J, Kenney A, Pendergrass D, Cooper M, Costanzo S, Muniyappa B, Carlston K, Hill J, Begaye L, Fortenberry KT, Cheng M, Smid MC, Cochran G (2021). Substance Use In Pregnancy: Addiction, Dependence, and Recovery, in Carbon, Emery, and San Juan Counties.
  16. White AH, Garets M, Foringer J, Dahlem CH, Beck MC, Soske J, Barnes J, Eckhardt D, Feldstein K, O'Donnell N, Britton J, Lugo H, Filimoeatu L, Labelle CT, Cochran G (2022). Medication for Opioid Use Disorder Toolkit for Peer Recovery Specialists.
  17. Cochran G, Kelley AT, Franks, LN, Reeves C, Incze MA, Gordon AJ, Sengpraseaut B, Gold C, Flake E, Carlston K, Wei Y (2025). Utah Medical Cannabis: A Prospective Cohort Evaluation 12-Month Report of Results.
  18. Cochran G, Franks L, Sengpraseut B, Broussard G (2026). 2025 Utah medical cannabis market analysis.

Video/Film/CD/Web/Podcast

  1. Cochran (2018). Improving Opioid Addiction Treatment for Pregnant Women.